Hercules Capital, Inc. (HTGC) - Q3 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024. Hercules Capital, Inc. is an internally managed, non-diversified closed-end management investment company regulated as a Business Development Company (BDC) under the Investment Company Act of 1940. The Company focuses on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in technology and life sciences industries.
Key Financial Metrics
| Metric | Q3 2024 (Three Months) | Q3 2023 (Three Months) | YTD 2024 (Nine Months) | YTD 2023 (Nine Months) |
|---|---|---|---|---|
| Total Investment Income | $125.2 million | $116.7 million | $371.8 million | $338.1 million |
| Net Investment Income | $83.2 million | $76.8 million | $244.7 million | $218.0 million |
| Net Increase in Net Assets from Operations | $68.7 million | $28.0 million | $201.5 million | $217.3 million |
| Net Asset Value (NAV) per Share | $11.40 | $10.93 | $11.40 | $10.93 |
| Total Assets | $3.66 billion | $3.42 billion | $3.66 billion | $3.42 billion |
| Total Debt (Carrying Value) | $1.74 billion | $1.55 billion | $1.74 billion | $1.55 billion |
| Cash and Cash Equivalents | $38.9 million | $98.9 million | $38.9 million | $98.9 million |
| Weighted Average Cost of Debt | 5.1% | 4.8% | 5.0% | 4.8% |
Material Changes vs. Prior Period
- Investment Income Growth: Total investment income increased 7.3% year-over-year for the quarter and 10.0% year-over-year for the nine-month period, driven by an increase in weighted average principal and dividend income, partially offset by a lower core yield.
- Unrealized Depreciation: The Company recorded a net change in unrealized depreciation of $13.9 million for the quarter and $45.0 million for the nine months ended September 30, 2024. This contrasts with $46.2 million and $6.3 million of depreciation in the comparable 2023 periods. The depreciation was primarily driven by debt investment valuation adjustments.
- Debt Levels: Total debt increased from $1.55 billion at year-end 2023 to $1.74 billion at September 30, 2024. This increase was funded by new borrowings under credit facilities and term notes to support portfolio growth.
- Portfolio Composition: The portfolio grew to $3.56 billion in fair value. The "Drug Discovery & Development" sector remains the largest at 31.6%, followed by "Software" at 28.6%.
- Non-Accrual Status: Non-accrual investments increased to 2.6% of the total portfolio at amortized cost ($92 million) from 1.0% ($31 million) at December 31, 2023.
Guidance, Outlook, and Risks
- Dividend Distribution: On October 24, 2024, the Board declared a cash distribution of $0.40 per share (base) plus a supplemental distribution of $0.08 per share, payable November 20, 2024. The Company estimates undistributed taxable earnings "spillover" of $0.94 per share as of September 30, 2024.
- Liquidity: As of September 30, 2024, the Company had approximately $572.3 million in available liquidity, including cash and available borrowing capacity under credit facilities and SBA debentures.
- Market Risks: The Company faces interest rate risk, with 97.3% of its debt portfolio bearing floating rates. While floors provide some insulation, rising rates increase the cost of floating-rate borrowings. Macroeconomic factors, including geopolitical conflicts and potential recession, pose risks to portfolio company performance.
- Concentration Risk: Five portfolio companies represented greater than 5% of net assets as of September 30, 2024: Axsome Therapeutics, Inc. (8.9%), Phathom Pharmaceuticals, Inc. (8.7%), Marathon Health, LLC (8.5%), Corium, Inc. (6.0%), and SeatGeek, Inc. (5.9%).
Investor Verification Checklist
- Unrealized Depreciation Drivers: Verify the specific portfolio companies contributing to the $45 million in YTD unrealized depreciation to assess credit quality trends.
- Non-Accrual Portfolio: Review the specific details of the $92 million in non-accrual investments and the Company's workout strategies for these assets.
- Debt Maturity Profile: Confirm the timing of debt maturities, noting $170 million due within one year and $1.22 billion due within 1-3 years.
- PIK Interest Impact: Assess the sustainability of distributions given the $37.9 million in Payment-in-Kind (PIK) interest income recorded YTD, which requires cash distribution despite not being collected in cash.
- Unfunded Commitments: Monitor the $489 million in available unfunded commitments and the potential capital deployment required to meet these obligations.